Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan ; volume:30 ; number:4 ; day:22 ; month:5 ; year:2023 ; pages:657-665 ; date:7.2023
Breast cancer ; 30, Heft 4 (22.5.2023), 657-665, 7.2023
- Urheber
-
Nozawa, K.
Terada, M.
Onishi, M.
Ozaki, Y.
Takano, T.
Fakhouri, W.
Novick, D.
Haro, J. M.
Faris, L. H.
Kawaguchi, T.
Tanizawa, Y.
Tsurutani, Junji
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-023-01461-6
- URN
-
urn:nbn:de:101:1-2023092210001452458726
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nozawa, K.
- Terada, M.
- Onishi, M.
- Ozaki, Y.
- Takano, T.
- Fakhouri, W.
- Novick, D.
- Haro, J. M.
- Faris, L. H.
- Kawaguchi, T.
- Tanizawa, Y.
- Tsurutani, Junji
- SpringerLink (Online service)
Ähnliche Objekte (12)
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer